Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $21.67

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $21.6667.

BCRX has been the subject of a number of research analyst reports. Citizens Jmp increased their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Wedbush reduced their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Needham & Company LLC lowered their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX traded up $0.01 on Thursday, hitting $10.18. The stock had a trading volume of 1,064,706 shares, compared to its average volume of 5,187,301. The stock has a market cap of $2.59 billion, a P/E ratio of -5.70 and a beta of 0.55. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $10.94. The firm’s fifty day simple moving average is $8.99 and its two-hundred day simple moving average is $8.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 EPS. Equities research analysts predict that BioCryst Pharmaceuticals will post -2.63 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BCRX. Larson Financial Group LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth purchased a new position in BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $81,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in BioCryst Pharmaceuticals in the third quarter worth $81,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.